Novartis Wins European Backing for Psoriasis Drug Cosentyx
This article is for subscribers only.
Novartis AG won European backing for a treatment against psoriasis that will compete with Amgen Inc.’s Enbrel and may garner more than $1 billion in annual sales.
Novartis’s secukinumab, which the company plans to sell under the brand name Cosentyx, was recommended by the European Medicine Agency’s Committee for Medicinal Products for Human Use, for the treatment of moderate-to-severe plaque psoriasis in adult patients, the Basel, Switzerland-based drugmaker said in a statement today. The European Commission, the EU’s executive arm, usually follows the panel’s advice.